title: Intranasal apomorphine. Nastech Pharmaceutical.
abstract: Nastech Pharmaceutical Co Inc is developing a nasal formulation of apomorphine for the potential treatment of erectile dysfunction and female sexual dysfunction.
authors.affiliation: Section of Andrology and Male Infertility, Department of Urology, Tulane University, Health Sciences Center, 1430 Tulane Avenue SL-4, New Orleans, LA 70112, USA. whellst@tulane.edu
authors.forename: Muammer
authors.initials: M
authors.lastname: Kendirci
authors.forename: Wayne J G
authors.initials: WJ
authors.lastname: Hellstrom
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy*; D013329:Structure-Activity Relationship
chemical_list: D018491:Dopamine Agonists; D001058:Apomorphine